Meet us at the ESPEN Congress in Milan, 7–10 September!

Logo TauroLock Logo TauroPharm


Our product range includes specialised catheter lock solutions for patients in different contexts. TauroLock™-U25.000 ensures a particularly strong prophylaxis against occlusion, thanks to the active ingredient urokinase.  


Indication and effect

TauroLock™-U25.000 has been approved for instillation in all central-venous access systems. This lock solution reliably prevents the formation of bacterial biofilms within catheters: Patients can avoid infections and maintain a high patency rate. 


TauroLock™-U25.000 is based on three active ingredients:

  • taurolidine
  • citrate (4 %)
  • urokinase (25,000 units)

Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE), while citrate works as an anticoagulant. Urokinase has a thrombolytic effect, breaking up blood clotting in its early stages.


Before applying TauroLock™-U25.000, you need to dissolve the vial’s content (i.e. 25,000 IU urokinase) with 5 ml of TauroLock™. In-between treatment sessions, instil the clear, colourless solution into the vascular access system (VAD). Please note that medical staff must respect the filling volume of each catheter or port system.

Expert recommendations

Taurolidine-based lock solutions such as TauroLock™-U25.000 are recommended in national and international guidelines




TauroLock™-U25.000 is contraindicated for patients who:

  • have a known allergy to taurolidine, citrate, or urokinase
  • are currently taking medication with known adverse interaction to citrate, taurolidine, or urokinase


Prior to the next treatment, TauroLock™-U25.000 must be aspirated and discarded in accordance with the applicable guidelines for infectious waste disposal. 

Package sizes

TauroLock™-U25.000 is available in vials of 5 ml (single dose, 5 vials per box). 

Storage & transport

TauroLock™-U25.000 must be stored at temperatures between 15 °C and 25 °C. Please note that you must not freeze TauroLock™-U25.000 under any circumstances.

More about TauroLock™-U25.000

National guideline recommendations, e.g. DGfN 2019:

“… taurolidine-citrate solutions may be considered … Another option is the intermittent (once weekly) use of urokinase as lock solution (Cat. IB).”

AIEOP recommendations for TauroLock™-U25.000 in oncology

Recommendations for locking the CVAD:


  1. The use of normal saline is recommended for locking CVADs. (A I)
    Randomized controlled trials have shown no difference between saline and heparinized solution. Saline is preferable due to the greater handling and the lower risk of side effects compared to heparin, especially in the newborn.
  2. Locking with non-antibiotic antibacterial substances (in particular, 2% taurolidine) has been proven effective in pediatric patients in reducing the risk of infection.
    Data on the pediatric cancer population are still limited. (BI)
  3. The use of thrombolytic substances (urokinase 5000 IU/ml or the tissue activator of plasminogen – rtPA 1 mg/ml) is recommended only in case of occlusion of the catheter lumen due to clots. (A II)

DGfN recommendations for TauroLock™-U25.000 in dialysis

“… taurolidine-citrate solutions may be considered … Another option is the intermittent (once weekly) use of urokinase as lock solution.” (Cat. IB)

Study by Winnicki et al. on taurolidine-based lock solutions in dialysis (2017)

“…Thus, use of taurolidine-based catheter lock solutions containing heparin and urokinase significantly reduced complications related to tunneled hemodialysis catheters when compared to four percent citrate solution and was overall more cost-efficient…”


Free access to all available materials

For personal inquiries, feel free to contact us via phone or email.

Our international distributors based in more than 50 countries will answer your requests ASAP.



We'll keep you posted on upcoming events, free download materials, and research insights.